Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Mansi, Janine"" wg kryterium: Autor


Tytuł :
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging
Autorzy :
Azad, Gurdip K.
Taylor, Benjamin P.
Green, Adrian
Sandri, Ines
Swampillai, Angela
Harries, Mark
Kristeleit, Hartmut
Mansi, Janine
Goh, Vicky
Cook, Gary J. R.Aff1, Aff3
Pokaż więcej
Źródło :
European Journal of Nuclear Medicine and Molecular Imaging. 46(4):821-830
Czasopismo naukowe
Tytuł :
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Autorzy :
Chan, Arlene
Moy, Beverly
Mansi, Janine
Ejlertsen, Bent
Holmes, Frankie Ann
Chia, Stephen
Iwata, Hiroji
Gnant, Michael
Loibl, Sibylle
Barrios, Carlos H.
Somali, Isil
Smichkoska, Snezhana
Martinez, Noelia
Garcia-Alonso, Mirta
Link, John S.
Mayer, Ingrid A.
Cold, Søren
Morales Murillo, Serafin
Senecal, Francis
Inoue, Kenichi
Pokaż więcej
Źródło :
Clinical Breast Cancer; Feb2021, Vol. 21 Issue 1, p80-91, 12p
Czasopismo naukowe
Tytuł :
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Autorzy :
Earl, Helena
Hiller, Louise
Vallier, Anne-Laure
Loi, Shrushma
McAdam, Karen
Hughes-Davies, Luke
Nigel Harnett, Adrian
Ah-See, Mei-Lin
Simcock, Richard
Rea, Daniel
Raj, Sanjay
Woodings, Pamela
Harries, Mark
Howe, Donna
Raynes, Kerry
Higgins, Helen B
Wilcox, Maggie
Plummer, Chris
Mansi, Janine
Gounaris, Ioannis
Mahler-Araujo, Betania
Provenzano, Elena
Chhabra, Anita
Abraham, Jean
Caldas, Carlos
Hall, Peter
McCabe, Christopher
Hulme, Claire
Miles, David
M Wardley, Andrew
Cameron, David
Dunn, Janet A
Pokaż więcej
Temat :
Article
Źródło :
Earl, H, Hiller, L, Vallier, A-L, Loi, S, McAdam, K, Hughes-Davies, L, Nigel Harnett, A, Ah-See, M-L, Simcock, R, Rea, D, Raj, S, Woodings, P, Harries, M, Howe, D, Raynes, K, Higgins, H B, Wilcox, M, Plummer, C, Mansi, J, Gounaris, I, Mahler-Araujo, B, Provenzano, E, Chhabra, A, Abraham, J, Caldas, C, Hall, P, McCabe, C, Hulme, C, Miles, D, M Wardley, A & Cameron, D & Dunn, J A 2019, ' 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial ', The Lancet, vol. 393, no. 10191 . https://doi.org/10.1016/S0140-6736(19)30650-6,">https://doi.org/10.1016/S0140-6736(19)30650-6, https://doi.org/10.1016/S0140-6736(19)30650-6
Opis pliku :
application/pdf
Tytuł :
Is response assessment of breast cancer bone metastases better with measurement of 18 F-fluoride metabolic flux than with measurement of 18 F-fluoride PET/CT SUV?
Autorzy :
Azad, Gurdip K.
Siddique, Musib
Taylor, Benjamin
Green, Adrian
O’Doherty, Jim
Gariani, Joanna
Blake, Glen M.
Mansi, Janine
Goh, Vicky
Cook, Gary J.R.
Pokaż więcej
Temat :
F-fluoride PET/CT
Bone metastases
Breast cancer
Heterogeneity
Radiology Nuclear Medicine and imaging
Źródło :
Azad, G K, Siddique, M, Taylor, B, Green, A, O’Doherty, J, Gariani, J, Blake, G M, Mansi, J, Goh, V & Cook, G J R 2019, ' Is response assessment of breast cancer bone metastases better with measurement of 18 F-fluoride metabolic flux than with measurement of 18 F-fluoride PET/CT SUV? ', Journal of Nuclear Medicine, vol. 60, no. 3, pp. 322-327 . https://doi.org/10.2967/jnumed.118.208710
Opis pliku :
application/pdf
Tytuł :
Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of 18F-Fluoride Metabolic Flux Than with Measurement of 18F-Fluoride PET/CT SUV?
Autorzy :
Azad, Gurdip K.
Siddique, Musib
Taylor, Benjamin
Green, Adrian
O’Doherty, Jim
Gariani, Joanna
Blake, Glen M.
Mansi, Janine
Goh, Vicky
Cook, Gary J.R.
Pokaż więcej
Temat :
Clinical
Oncology
breast cancer
bone metastases
heterogeneity, 18F-fluoride PET/CT
Źródło :
Journal of Nuclear Medicine
Tytuł :
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging
Autorzy :
Cook, Gary J. R.
Azad, Gurdip K.
Taylor, Benjamin P.
Green, Adrian
Sandri, Ines
Swampillai, Angela
Harries, Mark
Kristeleit, Hartmut
Mansi, Janine
Goh, Vicky
Pokaż więcej
Temat :
Original Article
Positron emission tomography/computed tomography
[18F]-sodium fluoride
[ F]-sodium fluoride
[ F]-fluorodeoxyglucose
Whole-body MRI
Bone metastases
Radiology Nuclear Medicine and imaging
[18F]-fluorodeoxyglucose
Diffusion-weighted MRI
Źródło :
European Journal of Nuclear Medicine and Molecular Imaging
Azad, G K, Taylor, B P, Green, A, Sandri, I, Swampillai, A, Harries, M, Kristeleit, H, Mansi, J, Goh, V J-L & Cook, G J R 2019, ' Prediction of therapy response in bone predominant metastatic breast cancer : Comparison of [18F-] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion weighted imaging. ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 4, pp. 821-830 . https://doi.org/10.1007/s00259-018-4223-9
Opis pliku :
application/pdf
Tytuł :
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Autorzy :
Martin, Miguel
Holmes, Frankie A
Ejlertsen, Bent
Delaloge, Suzette
Moy, Beverly
Iwata, Hiroji
von Minckwitz, Gunter
Chia, Stephen K L
Mansi, Janine
Barrios, Carlos H
Gnant, Michael
Tomašević, Zorica
Denduluri, Neelima
Šeparović, Robert
Gokmen, Erhan
Bashford, Anna
Ruiz Borrego, Manuel
Kim, Sung-Bae
Jakobsen, Erik Hugger
Ciceniene, Audrone
Inoue, Kenichi
Overkamp, Friedrich
Heijns, Joan B
Armstrong, Anne C
Link, John S
Joy, Anil Abraham
Bryce, Richard
Wong, Alvin
Moran, Susan
Yao, Bin
Xu, Feng
Auerbach, Alan
Buyse, Marc
Chan, Arlene
Langkjer, Sven Tyge
Pokaż więcej
Temat :
Administration, Oral
Adult
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Chemotherapy, Adjuvant
Disease-Free Survival
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Japan
Kaplan-Meier Estimate
Mastectomy
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Proportional Hazards Models
Quinolines
Receptor, ErbB-2
Risk Assessment
Survival Analysis
Time Factors
Trastuzumab
Treatment Outcome
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Źródło :
Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Chia, S K L, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Gokmen, E, Bashford, A, Ruiz Borrego, M, Kim, S-B, Jakobsen, E H, Ciceniene, A, Inoue, K, Overkamp, F, Heijns, J B, Armstrong, A C, Link, J S, Joy, A A, Bryce, R, Wong, A, Moran, S, Yao, B, Xu, F, Auerbach, A, Buyse, M, Chan, A, Langkjer, S T & ExteNET Study Group (Sven Tyge Langkjer; member) 2017, ' Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. ', The Lancet Oncology, vol. 18, no. 12, pp. 1688-1700 . https://doi.org/10.1016/S1470-2045(17)30717-9
Tytuł :
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET):5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Autorzy :
Martin, Miguel
Holmes, Frankie A.
Ejlertsen, Bent
Delaloge, Suzette
Moy, Beverly
Iwata, Hiroji
von Minckwitz, Gunter
Chia, Stephen K.L.
Mansi, Janine
Barrios, Carlos H.
Gnant, Michael
Tomašević, Zorica
Denduluri, Neelima
Šeparović, Robert
Gokmen, Erhan
Bashford, Anna
Ruiz Borrego, Manuel
Kim, Sung Bae
Jakobsen, Erik Hugger
Ciceniene, Audrone
Inoue, Kenichi
Overkamp, Friedrich
Heijns, Joan B.
Armstrong, Anne C.
Link, John S.
Joy, Anil Abraham
Bryce, Richard
Wong, Alvin
Moran, Susan
Yao, Bin
Xu, Feng
Auerbach, Alan
Buyse, Marc
Chan, Arlene
Cold, Soeren
Pokaż więcej
Temat :
Administration, Oral
Adult
Antibodies, Monoclonal, Humanized/adverse effects
Antineoplastic Combined Chemotherapy Protocols/administration & dosage
Breast Neoplasms/drug therapy
Chemotherapy, Adjuvant
Disease-Free Survival
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Japan
Kaplan-Meier Estimate
Mastectomy/methods
Middle Aged
Neoplasm Invasiveness/pathology
Neoplasm Staging
Proportional Hazards Models
Quinolines/administration & dosage
Receptor, ErbB-2/metabolism
Risk Assessment
Survival Analysis
Time Factors
Trastuzumab/administration & dosage
Treatment Outcome
Źródło :
ExteNET Study Group 2017, ' Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET) : 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet Oncology, vol. 18, no. 12, pp. 1688-1700 . https://doi.org/10.1016/S1470-2045(17)30717-9

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies